---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-262562"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:51:34.960536+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TuHURA starts Phase 3 IFx-2.0 trial, acquires TBS-2025, defers IFx-3.0

## Summary
- Initiated Phase 3 trial of IFx-2.0 + Keytruda in 1L Merkel cell carcinoma under FDA SPA for accelerated approval.
- Acquired VISTA-inhibiting mAb TBS-2025 via Kineta merger (June 2025); planning Phase 2 in mutNPM1 AML.
- Deferred development of IFx-3.0 mRNA candidate pending IFx-2.0 Phase 3 data; resources shifted to TBS-2025.
- Filed unaudited pro forma financials reflecting Kintara (Oct 2024) and Kineta (June 2025) mergers.

## SEC filing metadata
- accession: 0001193125-25-262562
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000119312525262562/0001193125-25-262562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000119312525262562/d73851d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-262562
- JSON: https://secwatch.observer/filing/0001193125-25-262562.json
- Plain text: https://secwatch.observer/filing/0001193125-25-262562.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.